tegafurgimerac相关论文
Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-sm
Objective Anlotinib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, has confirmed antitumor a......
